Biophytis S.A. (BPTSY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.28: the stock has moved about 72% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBiophytis S.A. (BPTSY) trades at $0.25. Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases. Their lead drug candidate, BIO101, targets neuromuscular diseases and respiratory failure. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for BPTSY: BPTSY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BPTSY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BPTSY: this read rests on a single discipline (Munger composite) — the other council disciplines have no scored data yet.
How is this calculated? →Biophytis S.A. (BPTSY) Healthcare & Pipeline Overview
Biophytis S.A. is a clinical-stage biotechnology company developing therapeutics for age-related diseases, including sarcopenia and macular degeneration. Their lead drug candidate, BIO101, addresses neuromuscular diseases and respiratory failure, positioning them in the regenerative medicine market with a focus on resilience pathways.
What Is the Investment Thesis for BPTSY?
Biophytis S.A. presents a high-risk, high-reward investment opportunity in the biotechnology sector. The investment thesis hinges on the successful clinical development and regulatory approval of BIO101 and BIO201. Key value drivers include positive clinical trial results, strategic partnerships, and potential market exclusivity. The company's focus on age-related diseases aligns with growing demographic trends and unmet medical needs. However, the company's negative P/E ratio of -0.07 reflects its current pre-revenue status. Investors should closely monitor clinical trial outcomes and regulatory milestones as key indicators of future success. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may not fully capture the inherent risks of investing in a clinical-stage biotech company.
Based on FMP financials and quantitative analysis
BPTSY Key Highlights
Biophytis S.A. is a clinical-stage biotechnology company focused on age-related diseases.
- Lead drug candidate BIO101 targets neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD).
- BIO201 is being developed for retinopathies, such as dry age-related macular degeneration and Stargardt disease.
- Collaboration agreement with AFM-Telethon supports the development of BIO101 for DMD.
- The company's P/E ratio is -0.07, reflecting its pre-revenue status.
Who Are BPTSY's Competitors?
BPTSY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
| RPRX Royalty Pharma plc | $58.75 | -3.04% | $26.0B | 725-pillar |
| INCY Incyte Corporation | $121.47 | -1.47% | $24.6B | 985-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BPTSY's Key Strengths?
Novel approach targeting resilience pathways.
- Lead drug candidate BIO101 in clinical development.
- Collaboration with AFM-Telethon.
- Experienced management team.
What Are BPTSY's Weaknesses?
Clinical-stage company with no current revenue.
- High reliance on successful clinical trial outcomes.
- Limited financial resources.
- OTC market trading with limited liquidity.
What Could Drive BPTSY Stock Higher?
Clinical trial results for BIO101 in sarcopenia patients.
- Clinical trial results for BIO101 in Duchenne Muscular Dystrophy (DMD) patients.
- Regulatory submissions for BIO101 in various indications.
- Advancement of BIO201 into clinical trials for AMD.
- Potential strategic partnerships and licensing agreements.
What Are the Key Risks for BPTSY?
Financial-distress signal — its Altman Z-Score of -16.95 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 6 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for BIO101 and BIO201.
- Regulatory delays or rejection of drug candidates.
- Competition from established pharmaceutical companies.
- Limited financial resources and need for additional funding.
- OTC market trading with limited liquidity and transparency.
What Are the Growth Opportunities for BPTSY?
- BIO101's potential to improve muscle function and reduce the risk of falls presents a significant growth opportunity. Clinical trials are ongoing, and positive results could lead to regulatory approval and commercialization within the next 3-5 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- BIO101 for Duchenne Muscular Dystrophy (DMD): DMD is a rare genetic disorder with limited treatment options. BIO101's collaboration with AFM-Telethon provides access to expertise and resources for developing a therapy for DMD. The DMD market is expected to grow as new therapies emerge. Regulatory approval could be expedited through orphan drug designation. The timeline for commercialization depends on the success of clinical trials and regulatory review, potentially within 5-7 years.
- BIO101 for COVID-19 Respiratory Failure: The COVID-19 pandemic has highlighted the need for effective treatments for respiratory failure. BIO101's potential to reduce inflammation and improve lung function could address this unmet need. The market size depends on the ongoing prevalence of COVID-19 and the emergence of new variants. Regulatory approval could be accelerated through emergency use authorization. The timeline for commercialization is uncertain but could be within the next 1-3 years.
- BIO201 for Age-Related Macular Degeneration (AMD): AMD is a leading cause of vision loss in older adults. BIO201's potential to slow the progression of dry AMD represents a significant growth opportunity. The AMD market is expected to grow as the population ages. Clinical trials are planned, and positive results could lead to regulatory approval and commercialization within the next 5-7 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- Strategic Partnerships and Licensing Agreements: Biophytis can expand its pipeline and market reach through strategic partnerships and licensing agreements. Collaborating with larger pharmaceutical companies or other biotech firms can provide access to funding, expertise, and distribution networks. Licensing out certain assets can generate revenue and reduce financial risk. The timeline for these opportunities is variable but could occur within the next 1-3 years.
What Are BPTSY's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Focus on resilience pathways, a novel approach to treating age-related diseases.
- Collaboration with AFM-Telethon for DMD research.
- Expertise in developing orally administered small molecule drugs.
What Does BPTSY Do?
Biophytis S.A., founded in 2006 and headquartered in Paris, France, is a clinical-stage biotechnology company dedicated to developing therapeutics that slow degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company's core strategy revolves around targeting and activating key biological resilience pathways, which protect against and counteract the effects of various biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that contribute to age-related diseases. Their lead drug candidate, BIO101, is an orally administered small molecule currently in development for treating neuromuscular diseases such as sarcopenia, Duchenne muscular dystrophy (DMD), and obesity. BIO101 is also being explored as a treatment for severe respiratory failure in patients suffering from COVID-19. In addition to BIO101, Biophytis is developing BIO201, another orally administered small molecule, aimed at treating retinopathies, including dry age-related macular degeneration and Stargardt disease. Biophytis has a collaboration agreement with AFM-Telethon for the development of BIO101 for DMD, highlighting strategic partnerships to advance their pipeline. The company employs 22 individuals.
What Products and Services Does BPTSY Offer?
- Develop therapeutics for age-related diseases.
- Target and activate key biological resilience pathways.
- Develop orally administered small molecule drugs.
- Focus on neuromuscular diseases like sarcopenia and DMD.
- Develop treatments for retinopathies like AMD.
- Collaborate with organizations like AFM-Telethon.
How Does BPTSY Make Money?
- Develop and commercialize proprietary drug candidates.
- Out-license drug candidates to larger pharmaceutical companies.
- Generate revenue through strategic partnerships and collaborations.
- Secure funding through venture capital and public offerings.
What Industry Does BPTSY Operate In?
Biophytis operates within the biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and significant market potential for successful therapies. The aging global population is driving increased demand for treatments targeting age-related diseases, creating a favorable market environment for companies like Biophytis. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies. Key trends include personalized medicine, gene therapy, and the use of artificial intelligence in drug discovery. Competitors include BITRF (BioTime Inc), BNGI (Bionomics Ltd), IPIX (Ipix Pharmaceuticals Inc), MCET (MGC Pharmaceuticals Ltd), and PFND (Profound Medical Corp).
Who Are BPTSY's Key Customers?
- Patients suffering from age-related diseases.
- Healthcare providers who prescribe Biophytis's therapies.
- Pharmaceutical companies that may license or acquire Biophytis's drug candidates.
- Research institutions and organizations interested in collaborating with Biophytis.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 45 |
| 2026-08-26 | 45 |
| 2026-08-29 | 45 |
| 2026-09-01 | 45 |
| 2026-09-04 | 45 |
| 2026-09-07 | 45 |
| 2026-09-10 | 45 |
What changed?
The score has stayed at 45.
Over the same 18 days the stock moved +0.0%.
Company Profile
Biophytis S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Stanislas Veillet. BPTSY has traded publicly since 2021.
Key Financial Metrics
Return on equity for Biophytis S.A. stands at 92.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.35 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Biophytis S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.95 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Biophytis S.A. has missed Wall Street's EPS estimate in 3 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 13435.2% below estimates on average.
Forward Outlook
Wall Street analysts project Biophytis S.A. revenue of about $2.0M for fiscal 2026, with EPS near $-1.71.
BPTSY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Novel approach targeting resilience pathways.
- Lead drug candidate BIO101 in clinical development.
- Collaboration with AFM-Telethon.
- Experienced management team.
Bear Case
- Clinical-stage company with no current revenue.
- High reliance on successful clinical trial outcomes.
- Limited financial resources.
- OTC market trading with limited liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BPTSY Latest News
No recent news available for BPTSY.
BPTSY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BPTSY.
Price Targets
Wall Street price target analysis for BPTSY.
BPTSY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BPTSY; grades run from A+ (80-100) to F (below 30).
Leadership: Stanislas Veillet
CEO
Stanislas Veillet serves as the CEO of Biophytis S.A., bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes roles in venture capital and business development, with a focus on identifying and developing innovative therapies. He has a strong understanding of the regulatory landscape and the challenges of bringing new drugs to market. His leadership is focused on advancing Biophytis's pipeline and securing strategic partnerships.
Track Record: Under Stanislas Veillet's leadership, Biophytis has advanced its lead drug candidate, BIO101, into clinical trials for multiple indications, including sarcopenia and DMD. He has also secured a collaboration agreement with AFM-Telethon, a significant milestone for the company. His strategic decisions have focused on targeting unmet medical needs in age-related diseases and building a strong intellectual property portfolio.
Biophytis S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. BPTSY is a Level 1 ADR, meaning it trades over-the-counter (OTC) and has less stringent reporting requirements than listed companies. It allows US investors to invest in Biophytis S.A. without directly dealing with foreign exchanges.
- Home Market Ticker: Euronext Growth Paris, France
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BPTS
BPTSY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biophytis S.A. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered more speculative and carries higher risks than exchange-listed stocks.
- OTC Tier: OTC Other
- Limited liquidity and trading volume.
- Lack of financial transparency and disclosure.
- Higher potential for price manipulation.
- Increased risk of fraud or mismanagement.
- Limited regulatory oversight.
- Review the company's filings on the OTC Markets website.
- Assess the company's financial health and operational performance.
- Research the management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Consult with a financial advisor.
- Consider the risks associated with investing in OTC stocks.
- Established business operations in France.
- Lead drug candidate in clinical development.
- Collaboration agreement with AFM-Telethon.
- Experienced management team.
- Focus on addressing unmet medical needs.
BPTSY Healthcare Stock FAQ
Is BPTSY a good stock?
Stock Expert AI does not rate BPTSY buy, sell or hold. Biophytis S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for BPTSY?
The main risks for Biophytis S.A. include the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company also faces financial risks due to its limited resources and need for additional funding.
What are the key factors to evaluate for BPTSY?
Evaluate BPTSY on fundamentals, analyst consensus, and risk factors. However, the company's negative P/E ratio of -0.07 reflects its current pre-revenue status. Not financial advice.
How frequently does BPTSY data refresh on this page?
BPTSY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BPTSY's recent stock price performance?
Biophytis S.A. (BPTSY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach targeting resilience pathways. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BPTSY overvalued or undervalued right now?
Biophytis S.A. (BPTSY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BPTSY?
Yes, most major brokerages offer fractional shares of Biophytis S.A. (BPTSY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BPTSY's earnings and financial reports?
Biophytis S.A. (BPTSY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BPTSY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.